- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
HC Wainwright Lowers Biohaven Price Target
Analysts cut price target on Biohaven stock to $10, citing neutral rating
Mar. 4, 2026 at 1:42pm
Got story updates? Submit your updates here. ›
HC Wainwright, an equity research firm, has decreased its price target on shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) from $11.00 to $10.00, while maintaining a "neutral" rating on the stock. This comes as the company faces challenges in its drug development pipeline and financial performance.
Why it matters
Biohaven is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. The lowered price target from a prominent research firm signals potential concerns about the company's near-term outlook and ability to deliver on its pipeline. This could impact investor sentiment and the stock's performance.
The details
In a research note, HC Wainwright cited the decreased price target and neutral rating, indicating that Biohaven's current stock price of $10.66 has limited upside potential. The firm noted that Biohaven has faced challenges, including a recent decline in its share price and uncertainty around the progress of its drug development programs.
- The updated price target and rating were issued on Wednesday, March 4, 2026.
The players
Biohaven Pharmaceutical Holding Company Ltd.
A clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases, headquartered in New Haven, Connecticut.
HC Wainwright
An equity research firm that provides investment banking and research services to public and private companies.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
The takeaway
The lowered price target from HC Wainwright reflects ongoing challenges for Biohaven, which will need to demonstrate progress in its drug development pipeline and financial performance to regain investor confidence and drive its stock price higher.
